Affordable Access

Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study.

Authors
  • Furrer, H
  • Telenti, A
  • Rossi, M
  • Ledergerber, B
Type
Published Article
Journal
AIDS
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Jul 07, 2000
Volume
14
Issue
10
Pages
1409–1412
Identifiers
PMID: 10930156
Source
Medline
License
Unknown

Abstract

Discontinuing or withholding primary prophylaxis against MAC is safe in patients who have a sustained increase in their CD4 cell count to > or = 100 x 10(6)/l.

Report this publication

Statistics

Seen <100 times